CST6 and Miyoshi myopathy: Nevertheless, the experimentally validated results of our correlative studies integrating both imaging and genomics in MM strongly suggest that CST6 represents a potent regulator of bone biology and potentially a new biological anti–bone-resorptive agent for the treatment of disease associated with osteoclast-mediated bone loss.